ArticleHuman vaccines & immunotherapeutics2019
Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States.
Article in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2023Guideline
- Drivers of and barriers to routine adult vaccination: A systematic literature review.Human vaccines & immunotherapeutics · 2022Pooled it
- A narrative review of HPV vaccination interventions in rural U.S. communities.Preventive medicine · 2021Pooled it
- Pneumococcal vaccination status in critically ill patients: A cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Factors associated with pneumococcal vaccine hesitancy and interventions to improve vaccine uptake in older adults: A narrative review using an established conceptual framework.Human vaccines & immunotherapeutics · 2026Review
- Health disparities in the burden of pneumococcal disease in US adults.Pneumonia (Nathan Qld.) · 2026Review
- Factors associated with willingness to accept pneumococcal vaccine based on the Health Belief Model among the elderly (≥60 years) living in Klang Valley, Malaysia.Human vaccines & immunotherapeutics · 2025Article
- Strengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States.Expert review of vaccines · 2025Review
- RSV vaccination uptake among adults aged 60 years and older in the United States during the 2023-2025 vaccination seasons.Human vaccines & immunotherapeutics · 2025Article
- A Cross-Sectional Survey to Identify Current Pneumococcal Vaccination Practices and Barriers in Rural Community Pharmacies.Vaccines · 2025Article
- Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination.JAMA network open · 2025Article
- Article
- Mobile Phone Text Message Reminders to Improve Vaccination Uptake: A Systematic Review and Meta-Analysis.Vaccines · 2024Review
- Association Between Social Vulnerability and Streptococcus pneumoniae Antimicrobial Resistance in US Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- County-Level Factors Associated With Influenza and COVID-19 Vaccination in Indiana, 2020‒2022.American journal of public health · 2024Article
- Patterns of basic pneumococcal conjugated vaccine coverage in Ethiopia from 2015 to 2018; further analysis of Ethiopian DHS (2016-2019).Vaccine: X · 2024Review
- A Nationwide Digital Multidisciplinary Intervention Aimed at Promoting Pneumococcal Vaccination in Immunocompromised Patients.Vaccines · 2023Article
- Pneumococcal vaccination coverage and adherence to recommended dosing schedules in adults: a repeated cross-sectional study of the INTEGO morbidity registry.BMC public health · 2023Article
- Disparities in vaccination rates in solid organ transplant patients.Transplant infectious disease : an official journal of the Transplantation Society · 2023Article
- Exposure, Susceptibility, and Recovery: A Framework for Examining the Intersection of the Social and Physical Environments and Infectious Disease Risk.American journal of epidemiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn September 2014, 13-valent pneumococcal conjugate vaccine (PCV13) was universally recommended for all US adults aged ≥65 years. Adult PCV13 coverage, including whether disparities in uptake exist, however, is not well-described.
methodsWe used a monthly series of cross-sectional analyses of administrative medical and prescription claims data collected by IQVIA and linked to sociodemographic data collected by Experian to estimate overall and subpopulation-level uptake of PCV13 among US adults aged ≥65 years.
resultsAmong adults aged ≥65 years, 43.3% received PCV13 by the end of November 2017. Race/ethnicity, annual household income, education status, and neighborhood urbanicity were strongly related to PCV13 uptake among adults aged ≥65 years. Lower uptake of PCV13 was observed for non-Hispanic black (36.3%) and Hispanic (30.0%) adults (vs 45.6% for non-Hispanic whites, P < .01), the poor (30.7% vs 54.2% among lowest vs highest income deciles, P < .01), adults with low educational status (33.0% vs 49.0% among those without high school education vs college educated, P < .01), and those living in rural communities (22.9%) or urban/inner-city (33.8%) areas (vs 45.8% in suburban areas, P < .01).
conclusionsPCV13 uptake among adults aged ≥65 occurred rapidly in the three years after universal recommendation in September 2014. Yet, poor and minority communities, rural and urban/inner-city areas, and communities with low educational attainment had substantially lower PCV13 coverage. These same populations are at increased risk of pneumococcal disease. In order to maximize the benefits of pneumococcal vaccination, further targeted and tailored interventions to increase PCV13 uptake in these underserved populations are still necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.